Doing what’s right isn’t easy. It isn’t easy to put people first. It isn’t easy to put innovative medicines into the hands of anyone, anywhere in the world. It’s time to do the hard stuff.
We are an innovative medicines biotechnology company committed to making healthcare more human. We will break down old silos and forge new alliances with any company that shares our mission. We will work tirelessly so that more people can have access to life-saving medicines. And, perhaps most importantly, we will impact not only the health, but the well-being of the people we serve.
11 pipeline programs in both oncology and non-oncology across all phases of development from preclinical to Phase 3
We plan to work within the structure of existing healthcare systems to implement tailored solutions that improve availability, accessibility, and affordability of our medicines
As a wholly owned subsidiary of Hengrui Pharma, we are a global development and commercialization biotechnology organization. By leveraging Hengrui Pharma’s established discovery and manufacturing capabilities, as well as a robust global clinical-trials network, we have the potential to bring innovative medicines to market quickly and efficiently.
Whether it’s rising out-of-pockets costs in the United States, restricted or delayed access in the European Union, or lack of availability in other regions, it’s time for a company to step up and address these unique challenges differently.
That’s why we are committed to tailoring solutions to local regions and healthcare ecosystems to overcome barriers and improve availability, accessibility, and affordability of innovative medicines.
Learn about our partnerships with purpose-driven companies.
Register to get the latest company news, updates, and information.
Stay tuned for future communications from Luzsana Biotechnology™.